Myeloid Malignancy malady

MalaCards: Myeloid Malignancy, also known as myeloid neoplasm, is related to acute myeloid leukemia and myeloproliferative disorder. An important gene associated with Myeloid Malignancy is CSF1R (colony stimulating factor 1 receptor), and among its related pathways are Immune response IFN gamma signaling pathway and Jak/Stat Pathway. The compounds vincristine and nadph have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and b cells, and related mouse phenotypes are respiratory system and limbs/digits/tail.

myeloid malignancy 7 myeloid neoplasm 43

Diseases related to myeloid malignancy by text searches and GeneDecks gene sharing:

(show top 50)    (show all 264)

id	Related Disease	Score	Top Affiliating Genes
1	acute myeloid leukemia	30.1	KIT, FLT3, NUP214, RUNX1
2	myeloproliferative disorder	26.9	KIT, MPL, JAK2, MLL, FLT3, ENG
3	chronic myeloid leukemia	24.4	KIT, MPL, JAK2, MLL, FLT3, MECOM
4	anemia	20.6	KIT, PARK2, ZBTB16, SBDS, MPL, JAK2
5	leukemia	16.7	NCOR2, KIT, PARK2, ZBTB16, SBDS, L3MBTL1
6	myeloid leukemia	15.9	NCOR2, KIT, PARK2, ZBTB16, L3MBTL1, MSI2
7	enchondroma	13.7	IDH1, IDH2, PTPN11
8	acute myelomonocytic leukemia	13.6	MLL, ETV6, CSF1R, RUNX1
9	chondroma	13.5	KIT, IDH1, IDH2, HMGA2
10	splenomegaly	13.5	MPL, JAK2, TET2, CSF3, RUNX1
11	secondary syphilis	13.5	CYP3A4, CYP3A5, CSF1R
12	essential thrombocythemia	13.5	MPL, JAK2, IDH1, IDH2, TET2, CSF3
13	bone marrow cancer	13.5	KIT, FLT3, NRAS
14	myeloid sarcoma	13.4	KIT, MLL, FLT3
15	spindle cell hemangioma	13.4	IDH1, IDH2
16	sm-ahnmd	13.4	KIT, JAK2, TET2, NRAS
17	myelofibrosis	13.4	KIT, MPL, JAK2, FLT3
18	chronic myeloproliferative disease	13.4	MPL, JAK2, FLT3, ETV6
19	acute lymphoblastic leukemia, childhood	13.4	CDKN1B, MLL, ETV6
20	mastocytosis	13.3	KIT, JAK2, CBL, TET2, NRAS
21	factor v leiden thrombophilia	13.2	MPL, JAK2, ENG, ANGPT2, PTPN11, ELANE
22	congenital mesoblastic nephroma	13.1	MLL, ETV6, WT1
23	brain cancer	13.1	GSTM1, GSTT1, NQO1
24	interval angle-closure glaucoma	13.1	IDH1, IDH2
25	mesoblastic nephroma	13.1	KIT, ETV6, WT1
26	chronic neutrophilic leukemia	13.0	MLL, CSF3
27	pancytopenia	13.0	MPL, MLL, WT1, CSF3
28	cblc	13.0	KIT, MPL, JAK1, JAK2, IL22RA2, CBL
29	tardive dyskinesia	13.0	GSTM1, GSTT1, CYP3A4, CYP3A5, NQO1
30	gastrointestinal system disease	13.0	KIT, CD40, DDX41, CYP3A4, ELANE
31	systemic lupus erythematosus	13.0	MPL, CD247, CD40, FCGR3A, PTPN11, TYK2
32	thrombocytosis	13.0	MPL, JAK1, JAK2, FLT3, MECOM, TET2
33	desmoplastic small round cell tumor	12.9	KIT, WT1, TSPAN7, CSF3
34	acute pancreatitis	12.9	GSTM1, GSTT1, ENG, A2M, ABCB7, ELANE
35	severe congenital neutropenia	12.9	FCGR3A, HLA-B, ELANE, CSF3
36	desmoid tumor	12.9	KIT, CDKN1B, CTNNA1, WT1
37	follicular lymphoma	12.9	CDKN1B, CD40, MLL, FCGR3A, HLA-B
38	sickle cell disease	12.9	FCGR3A, ENG, ANGPT2, DNMT1, CSF3, EPB41
39	basaloid squamous cell carcinoma	12.8	CDKN1B, ENG, TP53, CTNNA1
40	aplastic anemia	12.8	SBDS, MPL, FLT3, GSTM1, GSTT1, CYP3A4
41	chronic lymphocytic leukemia	12.8	JAK2, CD40, MLL, FLT3, CSF3R, HDAC9
42	megakaryocytic leukemia	12.8	JAK2, TP53, CSF1R, RUNX1
43	leukopenia	12.8	GSTM1, GSTT1, CYP3A4, CYP3A5, ABCB7, ELANE
44	thrombocytopenia	12.8	MPL, CDKN1B, FCGR3A, ABCB7, CSF3, RUNX1
45	chronic granulomatous disease	12.8	MLL, MECOM, ELANE, PRDM16, CSF3
46	uterine carcinosarcoma	12.7	KIT, ANG, ANGPT2, TP53
47	acute megakaryoblastic leukemia	12.7	KIT, MPL, JAK2, MLL, FLT3, ETV6
48	megakaryoblastic leukemia	12.7	KIT, MPL, JAK2, MLL, FLT3, ETV6
49	paroxysmal nocturnal hemoglobinuria	12.7	HMGA2, HLA-B, NRAS, WT1, CSF3
50	hemoglobinuria	12.7	FCGR3A, HMGA2, HLA-B, NRAS, WT1, CSF3

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to myeloid malignancy:

²²

MGI Mouse Phenotypes related to myeloid malignancy:

²⁵ (show all 24)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	respiratory system phenotype	MP:0005388	9.6	PARK2, CBL, AKAP12, PRDM16, CXCR7, GAS1
2	limbs/digits/tail phenotype	MP:0005371	9.2	ZBTB16, MLL, MECOM, CBL, NRAS, CTNNA1
3	endocrine/exocrine gland phenotype	MP:0005379	9.1	ZBTB16, CDKN1B, MLL5, CBFA2T2, ETV6, HMGA2
4	craniofacial phenotype	MP:0005382	8.8	MECOM, CBL, HMGA2, PTPN11, PRDM16, HDAC1
5	hearing/vestibular/ear phenotype	MP:0005377	8.7	NXF1, HMGA2, CSF1R, GAS1, PTPN11, MECOM
6	pigmentation phenotype	MP:0001186	8.6	PROM1, GAS1, KIT, CDKN1B, NXF1, DNMT1
7	digestive/alimentary phenotype	MP:0005381	8.6	KIT, NCOR2, CBFA2T2, NRAS, DNMT1, PRDM16
8	reproductive system phenotype	MP:0005389	8.2	MLL, CBL, ETV6, AKAP12, HMGA2, TET1
9	embryogenesis phenotype	MP:0005380	8.1	RUNX1, MPL, KIT, TET1, HDAC3, SBDS
10	no phenotypic analysis	MP:0003012	8.0	ETV6, CBFA2T3, FCGR3A, HDAC3, TP53, PROM1
11	liver/biliary system phenotype	MP:0005370	7.9	TET2, NQO1, ABCB7, RUNX1, HDAC3, EPB41
12	skeleton phenotype	MP:0005390	7.9	JARID2, MLL, CBL, CTNNA1, RUNX1, PRDM16
13	normal phenotype	MP:0002873	7.7	ETV6, RUNX1T1, SOCS1, PTPN7, AKAP12, DNMT1
14	integument phenotype	MP:0010771	7.5	CSF1R, NXF1, HMGA2, TP53, PTPN11, CTNNA1
15	muscle phenotype	MP:0005369	6.8	PTPN11, ENG, CBL, TP53, WT1, CXCR7
16	tumorigenesis	MP:0002006	6.8	DNMT1, PROM1, SOCS1, RUNX1, SIN3A, TSPAN33
17	hematopoietic system phenotype	MP:0005397	6.6	JAK1, KIT, ZBTB16, SBDS, L3MBTL1, MSI2
18	nervous system phenotype	MP:0003631	6.2	PTPN11, CTNNA1, JARID2, CDKN1B, CD247, MLL
19	cardiovascular system phenotype	MP:0005385	5.7	GAS1, AKAP12, RUNX1T1, HDAC1, KIT, HDAC3
20	immune system phenotype	MP:0005387	5.2	PRDM16, DNMT1, TSPAN33, TYK2, ELANE, WT1
21	homeostasis/metabolism phenotype	MP:0005376	4.7	NQO1, NRAS, PTPN11, ABCB7, ELANE, TYK2
22	cellular phenotype	MP:0005384	4.1	CTNNA1, WT1, ABCB7, TYK2, PROM1, NUP214
23	mortality/aging	MP:0010768	3.9	ABCB7, CTNNA1, PTPN11, TET2, TP53, ERC1
24	growth/size phenotype	MP:0005378	3.9	HDAC9, GAS1, HDAC1, RUNX1T1, ABCB7, DNMT1

Articles related to myeloid malignancy:

(show top 50)    (show all 64)

id	Title	Authors	Year	Affiliating Genes
1	AML1/RUNX1 gene point mutations in childhood myeloid malignancies. (21294243)	Migas A.... Aleinikova O.V.	2011	RUNX1
2	IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies. (21233841)	Oki K.... Ogawa S.	2011	IDH1, IDH2
3	CDKN1B, encoding the cyclin-dependent kinase inhibito r 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia. (21422114)	Haferlach C.... Haferlach T.	2011	CDKN1B
4	TP53 mutations in myeloid malignancies are either hom ozygous or hemizygous due to copy number-neutral loss of heterozygosity or dele tion of 17p. (19759556)	Jasek M.... Maciejewski J.P.	2010	TP53
5	Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. (20195608)	Bacher U.... Haferlach T.	2010	CBL, TET2
6	G-CSF and its receptor in myeloid malignancy. (20237318)	Beekman R.... Touw I.P.	2010	CSF3, CSF3R
7	A single-nucleotide polymorphism of the Fcgamma recep tor type IIIA gene in the recipient predicts transplant outcomes after HLA full y matched unrelated BMT for myeloid malignancies. (20400988)	Takami A.... Nakao S.	2010	FCGR3A
8	The idic(X)(q13) in myeloid malignancies: breakpoint clustering in segmental duplications and association with TET2 mutations. (20093295)	Paulsson K.... Johansson B.	2010	ABCB7, TET2
9	Mutations of e3 ubiquitin ligase cbl family members c onstitute a novel common pathogenic lesion in myeloid malignancies. (19901108)	Makishima H.... Maciejewski J.P.	2009	CBL, PARK2, CBLB
10	Progressive chromatin repression and promoter methyla tion of CTNNA1 associated with advanced myeloid malignancies. (19826047)	Ye Y.... Herman J.G.	2009	CTNNA1
11	Early epigenetic changes and DNA damage do not predic t clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. (19546476)	Fandy T.E.... Carraway H.E.	2009	DNMT1, HDAC9, SOCS1
12	The isochromosome i(7)(q10) carrying c.258+2t>c mutation of the SBDS gene does not promote development of myeloid malignancies in patients with Shwachman syndrome. (19148133)	Minelli A.... Danesino C.	2009	SBDS
13	Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies. (18483397)	Kumpers P.... Ganser A.	2008	ANGPT2
14	A novel RUNX1 mutation in familial platelet disorder with propensity to develop myeloid malignancies. (18166807)	Kirito K.... Komatsu N.	2008	RUNX1
15	250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. (19074904)	Dunbar A.J.... Maciejewski J.P.	2008	CBL
16	EVI1 overexpression in t(3;17) positive myeloid malignancies results from juxtaposition of EVI1 to the MSI2 locus at 17q22. (18815193)	De Weer A.... Poppe B.	2008	RUNX1, MSI2, MECOM
17	PR1 vaccination in myeloid malignancies. (18767937)	Rezvani K.	2008	ELANE, PRTN3
18	Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. (18723428)	Owen C.J.... Fitzgibbon J.	2008	RUNX1
19	A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene. (17690697)	Gorello P.... Mecucci C.	2008	ERC1
20	JAK and MPL mutations in myeloid malignancies. (18297515)	Tefferi A.	2008	JAK2, JAK3, TYK2
21	Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. (17875804)	Rezvani K.... Barrett A.J.	2008	WT1
22	An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. (17341266)	Bobadilla D.... Slovak M.L.	2007	MECOM
23	AKAP12, a gene with tumour suppressor properties, is a target of promoter DNA methylation in childhood myeloid malignancies. (17686059)	Flotho C.... Niemeyer C.M.	2007	AKAP12
24	Chemotherapy for myeloid malignancy in children with Fanconi anemia. (16609946)	Mehta P.A.... Davies S.M.	2007	CSF3
25	The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. (16204151)	Scott L.M.... Green A.R.	2005	JAK2
26	Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes. (15710585)	Rege-Cambrin G.... Hagemeijer A.	2005	FLT3, MLL
27	DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification. (15973457)	Garcon L.... Macintyre E.	2005	NUP214, DEK
28	Genetics of myeloid malignancies: pathogenetic and clinical implications. (16155011)	FrAPhling S.... Levine R.L.	2005	KIT, JAK2, FLT3
29	The human Penumbra gene is mapped to a region on chromosome 7 frequently deleted in myeloid malignancies. (16213355)	Chen Z.... Tsai S.	2005	TSPAN7, TSPAN33
30	Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. (15618963)	Odero M.D.... Cross N.C.	2005	HMGA2
31	Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications. (15128420)	Musolino C.... Calabro L.	2004	ANG
32	Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. (15123827)	Li J.... Green A.R.	2004	L3MBTL1
33	Differential levels of soluble endoglin (CD105) in myeloid malignancies. (12494455)	CalabrA^ L.... Maio M.	2003	ENG
34	Factors influencing the collection of peripheral blood stem cells in patients with acute myeloblastic leukemia and non-myeloid malignancies. (12479846)	Carral A.... Sanz M.A.	2003	CSF3
35	Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. (12531808)	Relling M.V.... Pui C.H.	2003	CSF3
36	FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies. (12191567)	de la Rubia J.... Sanz M.	2002	CSF3
37	MLL amplification in myeloid malignancies: clinical, molecular, and cytogenetic findings. (12034519)	Dolan M.... Hirsch B.	2002	MLL
38	Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. (12439220)	Blanco J.G.... Relling M.V.	2002	CYP3A4, CYP3A5, NQO1
39	The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t(16; 21)-positive myeloid malignancies. (12242670)	Hoogeveen A.T.... Sacchi N.	2002	HDAC1, HDAC3, NCOR2
40	A novel CBFA2 single-nucleotide mutation in familial platelet disorder with propensity to develop myeloid malignancies. (11675361)	Buijs A.... Lokhorst H.	2001	RUNX1
41	Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies. (11597142)	Kratz C.P.... Shannon K.M.	2001	MLL5
42	Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. (11369661)	Bianco T.... Dobrovic A.	2001	HLA-B
43	Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. (10673738)	Woo M.H.... Relling M.V.	2000	GSTT1, GSTM1
44	Monosomy 7 and 7q--associated with myeloid malignancy. (9218106)	Johnson E.... Cotter F.E.	1997	MLL5
45	TEL gene rearrangements in myeloid malignancy. (9443053)	Golub T.R.	1997	ETV6
46	The human CD40 gene lies within chromosome 20q deletions associated with myeloid malignancies. (8562382)	Asimakopoulos F.A.... Green A.R.	1996	CD40
47	Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. (8547101)	Secker-Walker L.M.... Bain B.	1995	PRDM16
48	A hematopoietic protein tyrosine phosphatase (HePTP) gene that is amplified and overexpressed in myeloid malignancies maps to chromosome 1q32.1. (8309248)	Zanke B.... Mak T.W.	1994	PTPN7, PTP4A2
49	Analysis of the p53 gene in myeloid malignancies associated with chromosomal abnormalities involving the short arm of chromosome 17. (8152298)	Rege-Cambrin G.... Saglio G.	1994	TP53
50	Localization of the human growth arrest-specific gene (GAS1) to chromosome bands 9q21.3-q22, a region frequently deleted in myeloid malignancies. (8307588)	Evdokiou A.... Cowled P.A.	1993	GAS1

Genes related to myeloid malignancy according to GeneCards:

(show top 50)    (show all 80)

id	Symbol	Description	Score	GeneCards Section Context
1	CSF1R	colony stimulating factor 1 receptor	11.1	Summaries
2	DDX10	DEAD (Asp-Glu-Ala-Asp) box polypeptide 10	11.0	Publications, Summaries
3	JARID2	jumonji, AT rich interactive domain 2	11.0	Summaries
4	RUNX1	runt-related transcription factor 1	11.0	Publications
5	GAS1	growth arrest-specific 1	11.0	Publications
6	TSPAN33	tetraspanin 33	11.0	Publications
7	CBLC	Cbl proto-oncogene, E3 ubiquitin protein ligase C	11.0	Publications
8	SBDS	Shwachman-Bodian-Diamond syndrome	11.0	Publications
9	L3MBTL1	l(3)mbt-like 1 (Drosophila)	11.0	Publications
10	PTPN7	protein tyrosine phosphatase, non-receptor type 7	11.0	Publications
11	PTP4A2	protein tyrosine phosphatase type IVA, member 2	11.0	Publications
12	CXCR7	chemokine (C-X-C motif) receptor 7	11.0	Expressions
13	IL22RA2	interleukin 22 receptor, alpha 2	11.0	Publications
14	NXF1	nuclear RNA export factor 1	11.0	Publications
15	TET3	tet methylcytosine dioxygenase 3	11.0	Publications
16	TET2	tet methylcytosine dioxygenase 2	11.0	Publications
17	CBFA2T3	core-binding factor, runt domain, alpha subunit 2; translocated to, 3	11.0	Publications
18	IDH2	isocitrate dehydrogenase 2 (NADP+), mitochondrial	11.0	Publications
19	DEK	DEK oncogene	11.0	Publications
20	IDH1	isocitrate dehydrogenase 1 (NADP+), soluble	11.0	Publications
21	ANG	angiogenin, ribonuclease, RNase A family, 5	11.0	Publications
22	MLL5	myeloid/lymphoid or mixed-lineage leukemia 5 (trithorax homolog, Drosophila)	11.0	Publications
23	HMGA2	high mobility group AT-hook 2	11.0	Publications
24	FCGR3A	Fc fragment of IgG, low affinity IIIa, receptor (CD16a)	11.0	Publications
25	CD247	CD247 molecule	11.0	Publications
26	TSPAN7	tetraspanin 7	11.0	Publications
27	TYK2	tyrosine kinase 2	11.0	Publications
28	MPL	myeloproliferative leukemia virus oncogene	11.0	Publications
29	HDAC3	histone deacetylase 3	11.0	Publications
30	NRAS	neuroblastoma RAS viral (v-ras) oncogene homolog	11.0	Publications
31	SIN3A	SIN3 transcription regulator homolog A (yeast)	11.0	Publications
32	SOCS1	suppressor of cytokine signaling 1	11.0	Publications
33	RUNX1T1	runt-related transcription factor 1; translocated to, 1 (cyclin D-related)	11.0	Publications
34	TET1	tet methylcytosine dioxygenase 1	11.0	Publications
35	PRTN3	proteinase 3	11.0	Publications
36	NUP98	nucleoporin 98kDa	11.0	Functions, Publications
37	NUP214	nucleoporin 214kDa	11.0	Publications
38	CSF3R	colony stimulating factor 3 receptor (granulocyte)	11.0	Publications
39	A2M	alpha-2-macroglobulin	11.0	Publications
40	DDX41	DEAD (Asp-Glu-Ala-Asp) box polypeptide 41	11.0	Publications
41	ENG	endoglin	11.0	Publications
42	CBL	Cbl proto-oncogene, E3 ubiquitin protein ligase	11.0	Publications
43	CBFA2T2	core-binding factor, runt domain, alpha subunit 2; translocated to, 2	11.0	Publications
44	AKAP12	A kinase (PRKA) anchor protein 12	11.0	Publications
45	ABCB7	ATP-binding cassette, sub-family B (MDR/TAP), member 7	11.0	Publications
46	ANGPT2	angiopoietin 2	11.0	Publications
47	NQO1	NAD(P)H dehydrogenase, quinone 1	11.0	Publications
48	CTNNA1	catenin (cadherin-associated protein), alpha 1, 102kDa	11.0	Publications
49	ZBTB16	zinc finger and BTB domain containing 16	11.0	Publications
50	CYP3A5	cytochrome P450, family 3, subfamily A, polypeptide 5	11.0	Publications

Pathways related to myeloid malignancy according to GeneDecks:

(show all 40)

id	Pathway	Score	Top Affiliating Genes
1	Immune response IFN gamma signaling pathway10	10.6	SOCS1, JAK2
2	Jak/Stat Pathway3	10.4	JAK2, SOCS1, TYK2, JAK1
3	Immune response IFN alpha/beta signaling pathway10	10.3	SOCS1, PTPN11, JAK1, TYK2
4	Development_Thrombopoetin signaling via JAK-STAT pathway41	10.3	PTPN11, CDKN1B, JAK2, MPL
5	Immune response_IFN alpha/beta signaling pathway41	10.3	JAK1, PTPN11, TYK2, SOCS1
6	Development Thrombopoetin signaling via JAK-STAT pathway10	10.3	SOCS1, PTPN11, CDKN1B, MPL, JAK2
7	Development_EPO-induced Jak-STAT pathway41	10.3	PTPN11, CBL, JAK2, SOCS1
8	Development EPO-induced Jak-STAT pathway10	10.2	PTPN11, SOCS1, CBL, JAK2
9	Imatinib Pathway, Pharmacokinetics/Pharmacodynamics34	10.2	CYP3A4, CYP3A5
10	Immune response_IFN gamma signaling pathway41	10.2	PTPN11, JAK1, JAK2, CBL, SOCS1
11	CNTF Signaling36	10.2	JAK2, JAK1, NRAS, TYK2
12	Akt Signaling36	10.2	CSF3R, FLT3, KIT, GAS1, NRAS
13	ErbB signaling pathway20	10.2	CBLB, NRAS, CBLC, CBL, CDKN1B
14	IL-22 Pathway36	10.1	TYK2, IL22RA2, JAK1
15	Acute myeloid leukemia20	10.1	RUNX1, ZBTB16, RUNX1T1, NRAS, FLT3, KIT
16	STAT3 Pathway36	10.1	ANGPT2, CSF3, CSF1R, SOCS1, TYK2, CSF3R
17	Platinum Pathway, Pharmacokinetics/Pharmacodynamics34	10.1	GSTM1, GSTT1, NQO1
18	Hematopoietic cell lineage20	9.9	CSF1R, CSF3R, CSF3, KIT, FLT3
19	Tyrosine Kinases / Adaptors3	9.8	CBL, JAK2, FLT3, ANGPT2, CBLB, CSF1R
20	Macrophage Differentiation and Growth Inhibition by METS36	9.8	HDAC3, HDAC9, HDAC1, SIN3A, CSF1R, NCOR2
21	TGF-beta Signaling Pathways37	9.8	SIN3A, RUNX1, PRDM16, ENG, NCOR2
22	Notch Signaling36	9.8	HDAC1, HDAC9, HDAC3, NCOR2
23	Protein Acetylation and Deacetylation36	9.7	HDAC1, HDAC3, HDAC9, NCOR2, SIN3A
24	Cytokine-cytokine receptor interaction20	9.7	CSF3R, KIT, CXCR7, IL22RA2, FLT3, CD40
25	DNA Methylation and Transcriptional Repression36	9.7	HDAC1, SIN3A, DNMT1, HDAC3, HDAC9
26	Jak-STAT signaling pathway20	9.7	SOCS1, CSF3, CBL, MPL, JAK1, JAK2
27	JAK-STAT Pathway36	9.7	MPL, KIT, JAK2, FLT3, NRAS, TYK2
28	Lymphocyte Signaling3	9.6	KIT, MECOM, RUNX1, CBL, CBLB, NQO1
29	Etoposide Pathway, Pharmacokinetics/Pharmacodynamics34	9.4	CYP3A5, GSTT1, CYP3A4
30	Molecular Mechanisms of Cancer36	9.2	ANGPT2, CBL, NRAS, CDKN1B, JAK1, CSF1R
31	Measles20	9.2	TYK2, TP53, CDKN1B, JAK2, JAK1, CBLB
32	Estrogen Pathway36	9.2	NCOR2, KIT, NRAS, CSF1R, FLT3, SIN3A
33	Immune System38	9.1	JAK1, CD247, CD40, FCGR3A, CBLB, HLA-B
34	G1-S Phase Transition36	9.0	HDAC1, HDAC9, HDAC3, CDKN1B, TP53
35	Cyclins and Cell Cycle Regulation36	9.0	HDAC3, CDKN1B, TP53, HDAC9, HDAC1
36	Pancreatic Adenocarcinoma36	9.0	CSF1R, KIT, JAK2, CDKN1B, FLT3, TP53
37	Huntingtons Disease Pathway36	8.9	SIN3A, NCOR2, TP53, HDAC1, HDAC3, HDAC9
38	Chronic myeloid leukemia20	8.8	CBLC, CBLB, CBL, CDKN1B, PTPN11, HDAC1
39	p38 Signaling36	8.7	CSF3R, GAS1, KIT, FLT3, TP53, NRAS
40	Pathways in cancer20	8.2	ZBTB16, CDKN1B, HDAC1, RUNX1T1, JAK1, FLT3

Compounds related to myeloid malignancy according to GeneDecks:

(show top 50)    (show all 119)

id	Compound	Score	Top Affiliating Genes
1	vincristine32 34 9 9	13.3	KIT, MLL
2	nadph32 18	11.1	CYP3A4, CYP3A5, IDH2, IDH1, PRTN3
3	trans,trans-muconic acid32	10.0	GSTM1, NQO1, GSTT1
4	3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3-oxopropanenitrile9 9	11.0	TYK2, JAK1, JAK3, JAK2
5	2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZ[H]-IMIDAZ[4,5-F]ISOQUINOLIN-7-ONE9 9	10.9	JAK2, JAK1, JAK3, TYK2
6	vanadate32	9.9	TYK2, JAK1, PTP4A2, PTPN11, CTNNA1, JAK2
7	sunitinib32 9 9	11.8	CSF1R, CYP3A5, CYP3A4, FLT3, KIT
8	gemtuzumab ozogamicin32 9 9	11.6	WT1, CSF3, FCGR3A, FLT3
9	threonine32	9.6	WT1, CSF1R, PTP4A2, FLT3, MLL, CDKN1B
10	gp 13032	9.5	JAK1, MPL, JAK2, KIT, FLT3, PTPN11
11	ifosfamide32 9 9	11.5	CYP3A4, CYP3A5, CSF3, GSTM1, GSTT1
12	p00332	9.4	HLA-B, FLT3, CDKN1B, KIT
13	agar32	9.4	ETV6, NRAS, NQO1, HDAC9, CSF1R, ENG
14	valine32	9.2	CSF3, ELANE, FCGR3A, GSTT1, GSTM1, JAK2
15	prednisolone32 9 9	11.2	MLL, CSF3, RUNX1, CYP3A4, CD40, GSTM1
16	h2o232	9.2	PARK2, JAK1, NQO1, CD40, CBL, PTPN11
17	aflatoxin b132 18	10.0	CYP3A4, GSTT1, TP53, CYP3A5, GSTM1
18	phosphotyrosine32	9.0	JAK2, FLT3, FCGR3A, CBL, HLA-B, PTP4A2
19	estrogen32	8.9	PRTN3, WT1, CYP3A5, ANGPT2, ENG, PARK2
20	cysteine32	8.9	DNMT1, CD40, GSTM1, ENG, ANGPT2, HDAC9
21	fludarabine32 9 9	10.6	DNMT1, CDKN1B, CSF3, CD40, HDAC9, TP53
22	etoposide32 42 9 9	11.5	HDAC1, TP53, HDAC9, CDKN1B, RUNX1, CSF1R
23	progesterone32 42 9 18 9	12.5	HDAC1, DNMT1, ABCB7, WT1, CYP3A5, NCOR2
24	glycogen32 18	9.3	JAK2, JAK1, PARK2, KIT, HDAC9, CDKN1B
25	lysine32	8.3	CDKN1B, HDAC9, PARK2, HDAC3, HDAC1, CSF3R
26	cytarabine32 34 9 9	11.2	NQO1, CYP3A4, FLT3, CDKN1B, CSF1R, KIT
27	cycloheximide32	8.1	CDKN1B, JAK1, CD40, KIT, JAK2, CSF3R
28	5fluorouracil32	8.1	TP53, MPL, KIT, NQO1, CSF3, HDAC9
29	butyrate32	8.0	HDAC9, JAK2, CDKN1B, CD40, TP53, WT1
30	paraffin32	8.0	KIT, CD40, CDKN1B, CSF1R, ANGPT2, HMGA2
31	phosphatidylinositol32	8.0	CSF1R, HDAC9, ANGPT2, JAK2, NCOR2, KIT
32	thymidine32 18	8.8	KIT, JAK2, CDKN1B, CD40, FLT3, TP53
33	tamoxifen32 34 9 9	10.8	CYP3A4, HDAC9, HDAC3, HDAC1, DNMT1, CYP3A5
34	dexamethasone32 42 34 9 9	11.8	CSF1R, HLA-B, CD40, JAK2, CSF3R, CDKN1B
35	5-aza-2deoxycytidine32	7.8	HDAC1, SOCS1, CTNNA1, TP53, HLA-B, FLT3
36	imatinib32 34 9 9	10.6	CBL, ETV6, FLT3, CDKN1B, JAK2, KIT
37	paclitaxel32 34 9 9	10.6	CTNNA1, KIT, CSF3, CYP3A5, CYP3A4, PARK2
38	doxorubicin32 34 9 9	10.5	GSTT1, ENG, HMGA2, TP53, CYP3A4, NQO1
39	proline32	7.4	PARK2, RUNX1, WT1, HLA-B, JAK1, JAK2
40	nitric oxide32 9 18 9	10.2	PTPN11, HLA-B, ANGPT2, ANG, CD40, CDKN1B
41	lipid32	7.0	CSF1R, HDAC1, HDAC9, GAS1, CD40, CD247
42	steroid32	6.9	GSTT1, CD40, JAK2, PARK2, KIT, NCOR2
43	zinc32 18	7.8	NCOR2, CBL, DNMT1, CD40, ABCB7, WT1
44	testosterone32 9 18 9	9.8	GSTM1, HDAC9, HDAC1, HLA-B, CYP3A4, CYP3A5
45	oxygen32 18	7.8	DNMT1, ELANE, ABCB7, HLA-B, NQO1, CSF3R
46	vegf32	6.0	ENG, TP53, CSF1R, CDKN1B, CD40, JAK1
47	oligonucleotide32	5.8	HLA-B, WT1, DNMT1, NUP98, CSF1R, RUNX1
48	serine32	5.2	ANGPT2, MLL, CSF3R, ENG, CD40, CDKN1B
49	retinoic acid32 42 18	6.5	HDAC9, HDAC3, HDAC1, RUNX1, CSF3R, CSF3
50	tyrosine32	4.4	HDAC9, NRAS, CTNNA1, PTPN11, PTPN7, PTP4A2

Cellular components related to myeloid malignancy according to GeneDecks:

id	Name	GO ID	Score	Top Affiliating Genes
1	transcriptional repressor complex	GO:017053	9.6	SIN3A, PRDM16, ZBTB16, NCOR2, HDAC3
2	histone deacetylase complex	GO:000118	9.0	MECOM, HDAC1, HDAC3, HDAC9
3	nucleoplasm	GO:005654	8.4	HDAC3, HDAC1, SIN3A, NUP98, WT1, NCOR2
4	cytosol	GO:005829	6.3	TP53, CBLB, CBL, IDH1, IL22RA2, GSTT1
5	nucleus	GO:005634	4.3	EPB41, CBLC, ETV6, HMGA2, TP53, TET1

Biological processes related to myeloid malignancy according to GeneDecks:

(show all 19)

id	Name	GO ID	Score	Top Affiliating Genes
1	glyoxylate cycle	GO:006097	10.4	IDH1, IDH2
2	regulation of type I interferon-mediated signaling pathway	GO:060338	10.3	PTPN11, TYK2, SOCS1, JAK1
3	regulation of interferon-gamma-mediated signaling pathway	GO:060334	10.2	SOCS1, PTPN11, JAK1, JAK2
4	myeloid progenitor cell differentiation	GO:002318	10.2	RUNX1, FLT3, KIT
5	hemopoiesis	GO:030097	10.1	KIT, L3MBTL1, RUNX1, FLT3, CSF1R, ZBTB16
6	chromatin modification	GO:016568	10.0	HDAC3, L3MBTL1, DEK, DNMT1, TET1, HDAC1
7	stem cell differentiation	GO:048863	10.0	JARID2, HMGA2, KIT
8	peptidyl-tyrosine phosphorylation	GO:018108	9.9	JAK1, KIT, FLT3, JAK2, CSF1R
9	positive regulation of phosphatidylinositol 3-kinase cascade	GO:014068	9.7	JAK2, CBL, FLT3, KIT
10	type I interferon-mediated signaling pathway	GO:060337	9.6	JAK1, SOCS1, TYK2, HLA-B, PTPN11
11	interferon-gamma-mediated signaling pathway	GO:060333	9.5	JAK1, JAK2, HLA-B, PTPN11, SOCS1
12	positive regulation of cell proliferation	GO:008284	9.3	CSF3, KIT, JAK2, CDKN1B, FLT3, NRAS
13	negative regulation of apoptotic process	GO:043066	8.9	TP53, HMGA2, CBL, CDKN1B, CTNNA1, WT1
14	cytokine-mediated signaling pathway	GO:019221	8.8	PTPN11, NUP98, KIT, JAK1, JAK2, FLT3
15	virus-host interaction	GO:019048	8.6	NUP98, NXF1, CXCR7, TP53, HLA-B, CD247
16	blood coagulation	GO:007596	8.4	JAK2, TP53, PTPN11, NRAS, A2M, HDAC1
17	positive regulation of transcription, DNA-dependent	GO:045893	8.2	MECOM, HMGA2, TP53, WT1, PRDM16, HDAC1
18	negative regulation of transcription from RNA polymerase II promoter	GO:000122	8.0	NCOR2, HDAC9, HDAC3, HDAC1, PRDM16, DNMT1
19	negative regulation of transcription, DNA-dependent	GO:045892	7.7	CDKN1B, PRDM16, WT1, TP53, L3MBTL1, HMGA2

Molecular functions related to myeloid malignancy according to GeneDecks:

(show all 16)

id	Name	GO ID	Score	Top Affiliating Genes
1	methylcytosine dioxygenase activity	GO:070579	10.6	TET1, TET2, TET3
2	growth hormone receptor binding	GO:005131	10.4	TYK2, JAK2, JAK1
3	isocitrate dehydrogenase (NADP+) activity	GO:004450	10.3	IDH1, IDH2
4	phosphotyrosine binding	GO:001784	10.2	CBLB, CBLC, CBL
5	protein deacetylase activity	GO:033558	9.9	HDAC1, HDAC3, HDAC9
6	transforming growth factor beta receptor, cytoplasmic mediator activity	GO:005072	9.9	ENG, CDKN1B
7	cytokine binding	GO:019955	9.9	CSF1R, ELANE, KIT
8	NAD-dependent histone deacetylase activity (H3-K14 specific)	GO:032041	9.8	HDAC9, HDAC3, HDAC1
9	NAD-dependent histone deacetylase activity (H4-K16 specific)	GO:046970	9.8	HDAC1, HDAC3, HDAC9
10	NAD-dependent histone deacetylase activity (H3-K9 specific)	GO:046969	9.8	HDAC9, HDAC1, HDAC3
11	histone deacetylase activity	GO:004407	9.7	HDAC9, HDAC3, HDAC1
12	protein homodimerization activity	GO:042803	9.2	RUNX1T1, KIT, ZBTB16, CD247, MLL, MECOM
13	transcription factor binding	GO:008134	8.7	HDAC1, HDAC9, HDAC3, TP53, DNMT1, RUNX1
14	enzyme binding	GO:019899	8.7	HDAC3, HDAC1, CSF3, PRTN3, CYP3A4, TP53
15	sequence-specific DNA binding transcription factor activity	GO:003700	8.1	TP53, L3MBTL1, MLL, MECOM, CBFA2T2, HDAC1
16	protein binding	GO:005515	2.7	DNMT1, ANGPT2, ANG, ENG, MECOM, FLT3